EN | TR
E-ISSN: 2602-2974
Effect of Heart Rate Control on Oxygenation and Vasopressor Need in Sepsis and Septic Shock-A Pilot Randomised Controlled Study
PDF
Cite
Share
Request
Original Research
VOLUME: 18 ISSUE: 4
P: 195-204
December 2020

Effect of Heart Rate Control on Oxygenation and Vasopressor Need in Sepsis and Septic Shock-A Pilot Randomised Controlled Study

J Turk Soc Intens Care 2020;18(4):195-204
DOI: 10.4274/tybd.galenos.2019.04934
Emre Sertaç Bingül 1
Günseli Orhun 2
Perihan Ergin Özcan 2
Figen Esen 2
1. Recep Tayyip Erdoğan Üniversitesi Eğitim ve Araştırma Hastanesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Rize, Türkiye
2. Recep Tayyip Erdoğan Üniversitesi Eğitim ve Araştırma Hastanesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, Rize, Türkiye
3. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, İstanbul, Türkiye
4. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Anesteziyoloji ve Reanimasyon Anabilim Dalı, İstanbul, Türkiye
No information available.
No information available
Received Date: 27.12.2018
Accepted Date: 19.10.2019
Publish Date: 25.12.2020
PDF
Cite
Share
Request

ABSTRACT

Objective:

The goal of this study was to examine the effect of keeping resting heart rate below 95 bpm on oxygenation, organ function, vasopressor need and mortality in sepsis and septic shock.

Materials and Methods:

Patients admitted to our intensive care unit with sepsis or septic shock diagnosis between June 2015 and July 2017 were included in the study. On the other hand, patients with a history of chronic β-blocker use, structural heart disease or permanent arrhythmia were excluded. After randomisation, patients in the study group (group BB) were given short-acting β1-blocker (esmolol) infusion to achieve resting heart rates between 85 and 95 bpm for 4 d. In both groups, 28-d mortality, vasopressor need and oxygenation parameters were recorded. Moreover, the results are presented as preliminary evaluation.

Results:

Fifty-two patients were included in the study. Further, 27 patients were in the group BB, while the remaining patients were in the control group (group NOBB). Pneumonia was the most common cause of sepsis (p>0.05). The APACHE II values in both groups were identical (p>0.05). Although the 28 d mortality rates decreased in the group BB, no statistical significance was observed due to insufficient sample size (p>0.05). The need for vasopressors also appeared to decrease on daily follow-up (p>0.05). In addition, the ratios of PaO2/FiO2 were higher in the group BB than in the group NOBB on day 3 (p<0.05). There was no difference in invasive mechanical ventilation, non-invasive mechanical ventilation, renal replacement therapy durations and length of stay (p>0.05). Also, no cardiac adverse effects associated with the intervention were observed.

Conclusion:

In this pilot study, we observed that cardio-selective β-adrenergic blockade could attenuate sepsis-related cardiac dysfunction. Decreased norepinephrine requirements and lactate levels, although not statistically significant, were consistent with a decrease in 28 d mortality rates. Despite enhanced oxygenation, mechanical ventilation durations did not vary in the group BB. In conclusion, we found that β1-receptor blockade had no detrimental effect on organ functions in sepsis. Moreover, it may be beneficial for cardiac and respiratory functions.

Keywords: Sepsis, shock, esmolol, heart rate

References

1
Levine HJ. Rest heart rate and life expectancy. J Am Coll Cardiol 1997;30:1104-6.
2
Verrier RL, Tan A. Heart rate, autonomic markers, and cardiac mortality. Heart Rhythm 2009;6(Suppl 11):S68-75.
3
Levine HJ, Wagman RJ. Energetics of the human heart. Am J Cardiol 1962;9:372-83.
4
Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-94.
5
Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM. Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J 2010;159:612-9.
6
Palatini P. Elevated heart rate: a “new” cardiovascular risk factor? Prog Cardiovasc Dis 2009;52:1-5.
7
Wannamethee G, Shaper AG, Macfarlane PW, Walker M. Risk factors for sudden cardiac death in middle-aged British men. Circulation 1995;91:1749-56.
8
Cook S, Togni M, Schaub MC, Wenaweser P, Hess OM. High heart rate: a cardiovascular risk factor? Eur Heart J 2006;27:2387-93.
9
La Rovere MT. Heart rate and arrhythmic risk: old markers never die. Europace 2010;12:155-7.
10
Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Prog Cardiovasc Dis 2009;52:46-60.
11
Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016;315:801-10.
12
Dunser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 2009;24:293-316.
13
Rudiger A. Beta-block the septic heart. Crit Care Med 2010;38(Suppl 10):S608-12.
14
Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care 2002;8:376-88.
15
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013;310:1683-91.
16
Orbegozo Cortes D, Njimi H, Dell’Anna AM, Taccone FS. Esmolol for septic shock: more than just heart rate control? Minerva Anestesiol 2014;80:254-8.
17
Schmittinger CA, Dunser MW, Haller M, Ulmer H, Luckner G, Torgersen C, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care 2008;12:R99.
18
Fox K, Ford I, Steg PG, Tendera M, Ferrari R, Investigators B. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:807-16.
19
Nuding S, Schroder J, Presek P, Wienke A, Muller-Werdan U, Ebelt H, et al. Reducing Elevated Heart Rates in Patients with Multiple Organ Dysfunction Syndrome with The If (Funny Channel Current) Inhibitor Ivabradine. Shock 2018;49:402-11.
20
Suzuki T, Suzuki Y, Okuda J, Kurazumi T, Suhara T, Ueda T, et al. Sepsis-induced cardiac dysfunction and beta-adrenergic blockade therapy for sepsis. J Intensive Care 2017;5:22.
21
Suzuki T, Morisaki H, Serita R, Yamamoto M, Kotake Y, Ishizaka A, et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005;33:2294-301.
22
Garnock-Jones KP. Esmolol: a review of its use in the short-term treatment of tachyarrhythmias and the short-term control of tachycardia and hypertension. Drugs 2012;72:109-32.
23
Yu SK, Tait G, Karkouti K, Wijeysundera D, McCluskey S, Beattie WS. The safety of perioperative esmolol: a systematic review and meta-analysis of randomized controlled trials. Anesth Analg 2011;112:267-81.
24
Balik M, Rulisek J, Leden P, Zakharchenko M, Otahal M, Bartakova H, et al. Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock. Reply to a letter to the authors. Wien Klin Wochenschr 2014;126:246-7.
25
Noveanu M, Breidthardt T, Reichlin T, Gayat E, Potocki M, Pargger H, et al. Effect of oral beta-blocker on short and long-term mortality in patients with acute respiratory failure: results from the BASEL-II-ICU study. Crit Care 2010;14:R198.
26
Fuchs C, Wauschkuhn S, Scheer C, Vollmer M, Meissner K, Kuhn SO, et al. Continuing chronic beta-blockade in the acute phase of severe sepsis and septic shock is associated with decreased mortality rates up to 90 days. Br J Anaesth 2017;119:616-25.
2024 ©️ Galenos Publishing House